{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:30:57Z","timestamp":1780569057422,"version":"3.54.1"},"reference-count":45,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Osteoporosis is a major risk factor for fracture and treatment is mainly preventive. Patients with severe psychiatric condition and treated with antipsychotics are at risk for vitamin D deficiency and iatrogenic hyperprolactinemia, two serious risk factors of osteoporosis. We aim to determine whether all antipsychotics are similar regarding the risk of osteoporosis in young patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>From January 2009 to March 2015, we determined the vitamin D blood level (VDBL) among 484 inpatients and from January 2012 to March 2015, we determined the prolactin blood level (PBL) among 205 inpatients. We systematically recorded well-documented risk factors (e.g., age, gender, ethnic origin, body mass index, or season) and suspected risk factors (e.g., disease type or antipsychotic treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Up to 89% of the inpatients had a VDBL under the recommended threshold. Up to 60% of the inpatients had hyperprolactinemia. The multivariate model found a significant effect on VDBL for seasonality (higher VDBL in summer), ethnicity (lower VDBL in Black individuals), and treatment exposure. The multivariate model found a significant effect on PBL for gender and treatment exposure. In both models, aripiprazole had a safer profile compared with other antipsychotics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Because adolescence is a period of bone construction and a critical window of opportunity for maximizing bone mass, we recommend vitamin D supplementation in young patients with severe mental condition. It could be interesting to reconsider to regularly monitor PBL among youth patients treated with antipsychotic, with the exception of aripiprazole.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2017.0158","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T10:35:39Z","timestamp":1542105339000},"page":"719-726","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":9,"title":["Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics"],"prefix":"10.1177","volume":"28","author":[{"given":"Marie","family":"Raffin","sequence":"first","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]},{"name":"Sorbonne Universit\u00e9","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bonnot","sequence":"additional","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Nantes University Hospital, Nantes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Giannitelli","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]},{"name":"Sorbonne Universit\u00e9","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Xavier","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]},{"name":"Sorbonne Universit\u00e9","place":["France"]},{"name":"CNRS UMR 7222, Institut des Syst\u00e8mes Intelligents et Robotiques, UPMC, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bodeau","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Bibrac","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Leban","sequence":"additional","affiliation":[{"name":"Pierre Louis Institute for Epidemiology and Public Health, Assistance Publique-H\u00f4pitaux de Paris, UPMC-GRC 08, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Line","family":"Menard","sequence":"additional","affiliation":[{"name":"Nice Children's Hospitals CHU-Lenval","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angele","family":"Consoli","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]},{"name":"Sorbonne Universit\u00e9","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cohen","sequence":"additional","affiliation":[{"name":"University Hospital Piti\u00e9-Salp\u00eatri\u00e8re","place":["France"]},{"name":"Sorbonne Universit\u00e9","place":["France"]},{"name":"CNRS UMR 7222, Institut des Syst\u00e8mes Intelligents et Robotiques, UPMC, Paris, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,12,10]]},"reference":[{"key":"e_1_3_3_2_1","first-page":"9","article-title":"Psychotropic medication in the French child and adolescent population: Prevalence estimation from health insurance data and national self-report survey data","author":"Acquaviva E","year":"2009","unstructured":"Acquaviva E, , Legleye S, , Auleley GR, , Deligne J, , Carel D, . Falissard BB: Psychotropic medication in the French child and adolescent population: Prevalence estimation from health insurance data and national self-report survey data. BMC Psychiatry , 9\u201372, 2009.","journal-title":"BMC Psychiatry"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1089\/104454602760219126"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.encep.2012.03.002"},{"key":"e_1_3_3_5_1","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller BM","year":"1992","unstructured":"Biller BM, , Baum HB, , Rosentha l DI, , Saxe VC, , Charpie PM, , Klibanski A: Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab, 75:692\u2013697, 1992.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_6_1","first-page":"57","article-title":"Proteins and bone health","volume":"45","author":"Bonjour JP","year":"1997","unstructured":"Bonjour JP, , Sch\u00fcrch MA, , Rizzoli R: Proteins and bone health. Pathol Biol (Paris), 45:57\u201359, 1997.","journal-title":"Pathol Biol (Paris)"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1232-3"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurenf.2009.09.004"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0079"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e31828f3c05"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.3111\/200104051062"},{"key":"e_1_3_3_12_1","unstructured":"Cavalli-Sforza LL Menozzi P Piazza A: The History and Geography of Human Genes. Princeton NJ Princeton University Press 1994."},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087373"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182549259"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1265"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.08.036"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-005-1867-7"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12042"},{"key":"e_1_3_3_20_1","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling RL","year":"2010","unstructured":"Findling RL, , Johnson JL, , McClellan J, , Frazier JA, , Vitiello B, , Hamer RM, , Lieberman JA, , Ritz L, , McNamara NK, , Lingler J, , Hlastala S, , Pierson L, , Puglia M, , Maloney AE, , Kaufman EM, , Noyes N, , Sikich L: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry, 49:583\u2013594, 2010.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.64.081501.131049"},{"key":"e_1_3_3_22_1","unstructured":"Governale L Mehta H: Outpatient use of Atypical Antipsychotic Agents in the Pediatric Population: Years 2004\u20132008. Retrieved 2009. July 26 2010 www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM193204.f 2010."},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464200-00003"},{"key":"e_1_3_3_24_1","first-page":"575","article-title":"Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth","volume":"16","author":"Ho J","year":"2011","unstructured":"Ho J, , Panagiotopoulos C, , McCrindle B, , Grisaru S, , Pringsheim T: Management recommendations for metabolic complications associated with second-generation antipsychotic use in children and youth. Paediatr Child Health, 16:575\u2013580, 2011.","journal-title":"Paediatr Child Health"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-006-0049-8"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-996-0028-z"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29449"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.1.162"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4266(06)72565-3"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2016.07.004"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e328355e1ac"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00011"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.16.575"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2012.01461.x"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-011020"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.63.6.679"},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107087346"},{"key":"e_1_3_3_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/16.9.581"},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-013-0007-9"},{"key":"e_1_3_3_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/135.11.2602"},{"key":"e_1_3_3_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11914-004-0016-0"},{"key":"e_1_3_3_42_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050756"},{"key":"e_1_3_3_43_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.110.3.e34"},{"key":"e_1_3_3_44_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-030817"},{"key":"e_1_3_3_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2387"},{"key":"e_1_3_3_46_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/167138"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2017.0158","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2017.0158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2017.0158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:54:54Z","timestamp":1777388094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2017.0158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1089\/cap.2017.0158"],"URL":"https:\/\/doi.org\/10.1089\/cap.2017.0158","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}